Roth Capital initiated coverage of Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC) with a Buy rating sending the stock price soaring 32 cents to close at $2.30.
Roth Capital Initiates Coverage Of Cyclacel
February 04, 2010 at 16:17 PM EST
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.